Characterization of Risk Factors for Genitourinary Infections with Sodium-Glucose Cotransporter-2 Inhibitors.

Background: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are associated with an increased risk of genitourinary infections in patients with type 2 diabetes mellitus (T2DM). It is unknown which factors may predispose patients to an increased risk of developing a genitourinary infection.

Objective: To evaluate whether hemoglobin A1c levels and other patient-specific factors at initiation of SGLT2 inhibitor therapy were a predictor for increased risk for genitourinary infections.